- IPO: 2005 (TSE: 4568)
- Market Cap: ~$70B (2026)
- 2025 Revenue: ¥1.5T
HSPA1A is a human gene whose product bAG2** (BCL2 Associated Athanogene 2) is a co-chaperone protein that modulates the Hsp70/Hsp90 chaperone systems. It contains a BAG domain that mediates interaction with Hsp70/Hsp90 ATPase domains, regulating their activity in protein folding and quality control. Variants in HSPA1A have been implicated in Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
[^2]
Gene Symbol
[^3]
BAG2
[^4]
Full Name
BCL2 Associated Athanogene 2
Chromosomal Location
9q22.33
NCBI Gene ID
[9532](https://www.ncbi.nlm.nih.gov/gene/9532)
OMIM
[603881](https://www.omim.org/entry/603881)
Ensembl ID
ENSG00000165168
UniProt ID
[O95817](https://www.uniprot.org/uniprot/O95817)
Protein
[BAG2-protein](/bag2-protein)
Associated Diseases
[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis), Cancer
BAG2 (BCL2 Associated Athanogene 2) is a co-chaperone protein that modulates the Hsp70/Hsp90 chaperone systems. It contains a BAG domain that mediates interaction with Hsp70/Hsp90 ATPase domains, regulating their activity in protein folding and quality control.
BAG2 functions as a co-chaperone with multiple roles:
- Hsp70 regulation: Binds to the ATPase domain of Hsp70 family proteins (HSPA1A, HSPA8, HSPA5) to regulate their chaperone activity
- Hsp90 regulation: Modulates Hsp90 chaperone complex function
- Protein quality control: Facilitates targeting of misfolded proteins for degradation
- Anti-apoptotic function: BAG family proteins inhibit apoptosis through various mechanisms
- Neuroprotection: Protects neurons from proteotoxic stress
BAG2 interacts with:
BAG2 is implicated in AD pathogenesis:
- Regulates clearance of tau protein aggregates
- Modulates Hsp70-mediated Aβ clearance
- BAG2 expression is altered in AD brain
- May have therapeutic potential for tauopathies [1][2]
In PD, BAG2 plays protective roles:
- Promotes clearance of alpha-synuclein (SNCA) aggregates
- Protects dopaminergic neurons from stress
- Coordinates with LRRK2 (LRRK2) pathway
- Autophagy regulation is key to PD protection [3]
In ALS:
- Helps clear TDP-43 aggregates (TARDBP)
- Protects against SOD1 mutant toxicity
- May compensate for defective protein homeostasis
- BAG2 levels correlate with disease progression [4]
BAG2 has complex roles in cancer:
- Often overexpressed in various cancers
- Promotes cell survival and chemoresistance
- Anti-apoptotic function through BCL2 interaction
BAG2 is expressed in various brain regions:
- Cerebral cortex: Moderate to high expression in pyramidal neurons
- Hippocampus: Strong expression in CA1-CA3 neurons
- Substantia nigra: Present in dopaminergic neurons
- Cerebellum: Expressed in Purkinje cells
- Glial cells: Detected in astrocytes and microglia
BAG2 expression is regulated by:
- Stress-responsive transcription factors
- Cellular stress conditions (heat shock, oxidative stress)
- Developmental stage
- Disease states (upregulated in neurodegeneration)
| Variant |
Type |
Effect |
Significance |
| rs2235067 |
Promoter |
Expression modifier |
May affect chaperone function |
| rs4149268 |
Coding |
Missense |
Cardiovascular disease link |
| rs2228671 |
Coding |
Synonymous |
Cancer associations |
- BAG2 modulators: Small molecules to enhance BAG2 function
- Hsp70/BAG2 interaction inhibitors: For cancer therapy
- Proteostasis enhancers: Boost protein clearance pathways
- Gene therapy for neurodegenerative diseases
- Combination with Hsp90 inhibitors
- Targeting protein aggregation in tauopathies